These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34087061)

  • 1. Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: A propensity score-adjusted analysis.
    Takahashi D; Mizuno T; Yokoyama Y; Igami T; Yamaguchi J; Onoe S; Watanabe N; Maeda O; Ando M; Ebata T
    J Hepatobiliary Pancreat Sci; 2021 Sep; 28(9):716-726. PubMed ID: 34087061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis.
    Mizuno T; Ebata T; Yokoyama Y; Igami T; Sugawara G; Yamaguchi J; Nagino M
    Surg Today; 2017 Feb; 47(2):182-192. PubMed ID: 27194019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
    Hosoda K; Fukushima K; Shimizu A; Motoyama H; Kubota K; Notake T; Sugenoya S; Hayashi H; Yasukawa K; Kobayashi R; Soejima Y
    Oncology; 2021; 99(11):703-712. PubMed ID: 34515195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.
    Li H; Zhang ZY; Zhou ZQ; Guan J; Tong DN; Zhou GW
    Oncotarget; 2016 May; 7(18):26888-97. PubMed ID: 27058753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma".
    Mungmungpuntipantip R; Wiwanitkit V
    J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):e28. PubMed ID: 34748290
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma".
    Takahashi D; Mizuno T; Ebata T
    J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):e29. PubMed ID: 34748277
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
    Jeong H; Kim KP; Jeong JH; Hwang DW; Lee JH; Kim KH; Moon DB; Lee MA; Park SJ; Chon HJ; Park JH; Lee JS; Ryoo BY; Yoo C
    Hepatology; 2023 May; 77(5):1540-1549. PubMed ID: 37070950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients.
    Akahoshi K; Ban D; Kuboki R; Oba A; Ono H; Mitsunori Y; Kudo A; Tanaka S; Tanabe M
    J Gastroenterol Hepatol; 2019 Jun; 34(6):1108-1115. PubMed ID: 30242888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete response of recurrent perihilar cholangiocarcinoma following sintilimab combined with lenvatinib plus S-1: a case report and review of literature.
    Liu QQ; Yu XH; Tang QB; Chen D; Zhang R; Liu C; Shi XD
    Anticancer Drugs; 2024 Jan; 35(1):81-85. PubMed ID: 37227031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
    Wirasorn K; Ngamprasertchai T; Khuntikeo N; Pakkhem A; Ungarereevittaya P; Chindaprasirt J; Sookprasert A
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1885-91. PubMed ID: 23829232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review.
    Belkouz A; Nooijen LE; Riady H; Franken LC; van Oijen MGH; Punt CJA; Erdmann JI; Klümpen HJ
    Cancer Treat Rev; 2020 Dec; 91():102110. PubMed ID: 33075684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Therapy Is Associated With Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study.
    Nassour I; Mokdad AA; Porembka MR; Choti MA; Polanco PM; Mansour JC; Minter RM; Wang SC; Yopp AC
    Ann Surg Oncol; 2018 May; 25(5):1193-1201. PubMed ID: 29488187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma.
    Matsuyama R; Mori R; Ota Y; Homma Y; Yabusita Y; Hiratani S; Murakami T; Sawada Y; Miyake K; Shimizu Y; Kumamoto T; Endo I
    Ann Surg Oncol; 2022 Apr; 29(4):2393-2405. PubMed ID: 34994885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study.
    Nooijen LE; Franken LC; Belkouz A; Oulad Abdennabi I; Besselink MG; Busch OR; Swijnenburg RJ; Klümpen HJ; Erdmann JI
    Am J Clin Oncol; 2021 Oct; 44(10):526-532. PubMed ID: 34469345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
    Morine Y; Shimada M; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Yamada S; Imura S
    Anticancer Res; 2017 Nov; 37(11):6421-6428. PubMed ID: 29061828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy for perihilar cholangiocarcinoma: A population-based comparative cohort study.
    Kamarajah SK; Al-Rawashdeh W; Parente A; Atherton P; Salti GI; Dahdaleh FS; Manas D; Hilal MA; White SA
    Eur J Surg Oncol; 2022 Jun; 48(6):1300-1308. PubMed ID: 34916085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.
    Brandi G; Deserti M; Vasuri F; Farioli A; Degiovanni A; Palloni A; Frega G; Barbera MA; de Lorenzo S; Garajova I; Di Marco M; Pinna AD; Cescon M; Cucchetti A; Ercolani G; D'Errico-Grigioni A; Pantaleo MA; Biasco G; Tavolari S;
    Oncologist; 2016 May; 21(5):600-7. PubMed ID: 27032872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study.
    Wang L; Deng M; Ke Q; Lou J; Zheng S; Bi X; Wang J; Guo W; Li F; Wang J; Zheng Y; Li J; Cheng S; Zhou W; Zeng Y
    Cancer Med; 2020 Apr; 9(8):2674-2685. PubMed ID: 32072774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.